Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Engineering a patient’s own immune cells to resist HIV could eliminate the need for lifelong antiretroviral therapies.
Tailor-made medical devices could give a more detailed picture of cardiac health and may be better at predicting and preventing problems.
Artificial tissue has always lacked a key ingredient: blood vessels. A new 3-D printing technique seems poised to change that.
By tracking an older person’s movements at home, a new wearable device could help predict serious changes in health.
A single-molecule gene test requires much less DNA to identify cancer-causing mutations.
Researchers find a way to turn pain on, and off, with a beam of light.
A new nerve interface gives a sense of touch to a prosthetic limb.
These VCs don’t wait for biotech startups to come to them. They create companies themselves.
After outflanking and outlasting competitors, it is on top of the genome-sequencing business—just as that market is about to soar in importance.